Statement of Changes in Beneficial Ownership (4)
March 10 2021 - 6:19PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Shenouda Maged |
2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC.
[
RLMD
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CFO |
(Last)
(First)
(Middle)
C/O RELMADA THERAPEUTICS, INC., 880 THIRD AVENUE, 12TH FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/8/2021 |
(Street)
NEW YORK, NY 10022
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 3/8/2021 | | M | | 10000 | A | $3.24 | 12228 | D | |
Common Stock | 3/8/2021 | | S(1) | | 100 | D | $35 | 12128 | D | |
Common Stock | 3/9/2021 | | S(1) | | 5727 (2) | D | $35.4212 (3) | 6401 | D | |
Common Stock | 3/9/2021 | | S(1) | | 1800 (2) | D | $36.02 (4) | 4601 | D | |
Common Stock | 3/10/2021 | | S(1) | | 2373 (2) | D | $35.1089 (5) | 2228 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Options to purchase common stock | $3.24 | 3/8/2021 | | M | | | 10000 | 10/20/2017 (6) | 10/20/2027 | Common Stock | 10000 | $0 (7) | 70350 | D | |
Explanation of Responses: |
(1) | The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. |
(2) | The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. |
(3) | Sales prices range from $35.02 to $35.95 per share, inclusive. |
(4) | Sales prices range from $36.02 to $36.51 per share, inclusive. |
(5) | Sales prices range from $35.00 to $35.37 per share, inclusive. |
(6) | The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. |
(7) | Not applicable |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Shenouda Maged C/O RELMADA THERAPEUTICS, INC. 880 THIRD AVENUE, 12TH FLOOR NEW YORK, NY 10022 |
|
| CFO |
|
Signatures
|
/s/ Maged Shenouda | | 3/10/2021 |
**Signature of Reporting Person | Date |
Relmada Therapeutics (NASDAQ:RLMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Relmada Therapeutics (NASDAQ:RLMD)
Historical Stock Chart
From Apr 2023 to Apr 2024